HUTCHMED (NASDAQ:HCM) Sets New 12-Month Low – Time to Sell?

HUTCHMED (China) Limited (NASDAQ:HCM)’s stock price hit a new 52-week low during trading on Wednesday . The company traded as low as $12.89 and last traded at $12.87, with a volume of 4366 shares changing hands. The stock had previously closed at $13.20.

Analysts Set New Price Targets

Separately, StockNews.com downgraded HUTCHMED from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.

HUTCHMED Stock Down 1.3 %

The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The firm’s 50-day moving average is $14.70 and its 200 day moving average is $17.14.

Institutional Investors Weigh In On HUTCHMED

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio acquired a new position in shares of HUTCHMED during the third quarter worth $35,000. Blue Trust Inc. lifted its holdings in HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after buying an additional 3,057 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in HUTCHMED by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock valued at $117,000 after buying an additional 2,321 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of HUTCHMED during the second quarter valued at about $213,000. Finally, Summit Trail Advisors LLC increased its position in shares of HUTCHMED by 14.4% during the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company’s stock worth $189,000 after acquiring an additional 1,647 shares during the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.